The generalized anxiety disorder market reached a value of USD 1.9 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 3.8 Billion by 2035, exhibiting a growth rate (CAGR) of 6.43% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 1.9 Billion |
Market Forecast in 2035
|
USD 3.8 Billion |
Market Growth Rate (2025-2035)
|
6.43% |
The generalized anxiety disorder market has been comprehensively analyzed in IMARC's new report titled "Generalized Anxiety Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Generalized anxiety disorder (GAD) refers to a mental health condition characterized by excessive and persistent worry or anxiety about various aspects of life. People suffering from the ailment often experience chronic and unrealistic concerns about everyday things, such as work, health, family, finances, etc., even when there is no apparent reason for the stress. This anxiety is typically difficult to control and may interfere with daily functioning and quality of life. The common symptoms of the illness include restlessness, fatigue, muscle tension, irritability, difficulty sleeping or concentrating, overthinking, indecisiveness, a constant feeling of tension, sweating, gastrointestinal problems, trembling, shortness of breath, etc. Diagnosing GAD typically involves a combination of clinical evaluation, medical history, and psychological testing. The diagnostic guidelines outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) are used to evaluate the presence and severity of disease symptoms. Additionally, several standardized questionnaires, such as the Generalized Anxiety Disorder 7-item scale (GAD-7) or the Penn State Worry Questionnaire (PSWQ), are recommended to rule out any medical conditions that could contribute to the underlying indications.
The increasing cases of imbalances or irregularities in certain neurotransmitters, like serotonin, norepinephrine, dopamine, etc., are primarily driving the generalized anxiety disorder market. In addition to this, the rising incidences of various associated risk factors, such as chronic exposure to stressful situations, trauma, genetic predisposition, abuse, significant life changes, etc., are also creating a positive outlook for the market. Moreover, the escalating adoption of effective medications, including benzodiazepines and selective serotonin reuptake inhibitors (SSRIs), to ease the symptoms of the illness is further bolstering the market growth. Apart from this, the emerging popularity of cognitive behavioral therapy, which helps in identifying and challenging negative or unhealthy thought patterns and replacing them with more realistic and positive ones, is also acting as another significant growth-inducing factor. Furthermore, the escalating application of mindfulness-based stress reduction techniques to treat this condition on account of their several benefits, like reduced anxiety symptoms, enhanced emotional regulation skills, increased resilience, improved overall well-being, etc., is expected to drive the generalized anxiety disorder market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the generalized anxiety disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for generalized anxiety disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the generalized anxiety disorder market in any manner.
Lexapro (Escitalopram Oxalate) is an antidepressant medicine used to treat generalized anxiety disorder in adults and children patients aged 7 years and older. The recommended starting dose of Lexapro for adults is 10 mg once a day, while the recommended starting dose for pediatric patients aged 7 years and above is 10 mg once daily.
SEP-363856, a TAAR1 agonist with 5-HT1A agonist action, is presently under investigation for the management of major depressive disorder and generalized anxiety disorder, with other indications under consideration.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current generalized anxiety disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Paxil (Paroxetine Hydrochloride) | GlaxoSmithKline |
Cymbalta (Duloxetine) | Lilly USA, LLC |
Effexor XR (Venlafaxine HCl) | Viatris Inc. |
Lexapro (Escitalopram Oxalate) | AbbVie |
ITI-1284 ODT-SL | Johnson & Johnson |
SEP-363856 | Otsuka Pharmaceutical Co., Ltd. |
MM120 (LSD D-Tartrate) | Mind Medicine Inc. |
ENX-102 | Engrail Therapeutics |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Generalized Anxiety Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies